Androgen deprivation as a strategy for prostate cancer chemoprevention.
Aquilina
J W
JW
Clinical Pharmacology Unit, Department of Pharmacology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Lipsky
J J
JJ
Bostwick
D G
DG
D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000502:physiology; D042944:Cholestenone 5 alpha-Reductase; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004967:Estrogens / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D011230:Precancerous Conditions / Q000188:drug therapy*; D019048:Prostatic Intraepithelial Neoplasia / Q000628:therapy; D011471:Prostatic Neoplasms / Q000503:physiopathology / Q000517:prevention & control* / Q000628:therapy
D000726:Androgen Antagonists; D000728:Androgens; D004791:Enzyme Inhibitors; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase